Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291226
Status:
COMPLETED
Last Update Posted:
2020-04-02
First Post:
2006-02-10
Brief Title:
Glycine vs Placebo for the Schizophrenia Prodrome
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
Glycine vs Placebo for the Schizophrenia Prodrome
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo
Detailed Description:
A pilot clinical trial comparing glycine to placebo in patients with the schizophrenia prodrome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None